Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Compass Pathways Plc ADR (CMPS)

Compass Pathways Plc ADR (CMPS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 639,473
  • Shares Outstanding, K 96,017
  • Annual Sales, $ 0 K
  • Annual Income, $ -287,860 K
  • EBIT $ -179 M
  • EBITDA $ -179 M
  • 60-Month Beta 2.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 116.82% (+20.79%)
  • Historical Volatility 68.81%
  • IV Percentile 38%
  • IV Rank 20.28%
  • IV High 287.30% on 06/20/25
  • IV Low 73.46% on 03/19/26
  • Expected Move (DTE 25) 1.23 (18.51%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 1,392
  • Volume Avg (30-Day) 2,103
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 89,786
  • Open Int (30-Day) 84,577
  • Expected Range 5.43 to 7.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.41
  • Number of Estimates 5
  • High Estimate $-0.30
  • Low Estimate $-0.58
  • Prior Year $-0.44
  • Growth Rate Est. (year over year) +6.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.88 +36.48%
on 03/24/26
6.95 -4.17%
on 04/17/26
+0.60 (+9.90%)
since 03/17/26
3-Month
4.88 +36.48%
on 03/24/26
8.90 -25.17%
on 02/18/26
-0.69 (-9.39%)
since 01/16/26
52-Week
2.25 +196.00%
on 06/23/25
8.90 -25.17%
on 02/18/26
+3.53 (+112.78%)
since 04/17/25

Most Recent Stories

More News
Trump Signs Psychedelics Order to Speed Ibogaine Research, Opening New Path for PTSD Treatment

President Donald Trump signed an executive order on April 18 directing the FDA to accelerate review pathways for psychedelic-based treatments including ibogaine, while committing $50 million to related...

CMPS : 6.66 (unch)
MNMD : 15.02 (+1.01%)
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments...

CMPS : 6.66 (unch)
 Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based organizations...

CMPS : 6.66 (unch)
Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Needham...

CMPS : 6.66 (unch)
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under...

CMPS : 6.66 (unch)
Compass Pathways Faces Critical Test as Losses Widen and Analyst Confidence Wavers

Barchart Research What to Expect from CMPS Earnings CMPS Generated March 25, 2026 Current Price $5.62 EPS Estimate $-0.47 Consensus Rating Strong Buy Average Move 9.84% Compass Pathways Faces Critical...

CMPS : 6.66 (unch)
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

COMP360 is the first classic psychedelic 1 to consistently achieve a highly statistically significant result and clinically meaningful effect in treatment resistant depression (TRD),...

CMPS : 6.66 (unch)
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Stifel...

CMPS : 6.66 (unch)
Cathie Wood Bets $19 Million on 5 Beaten-Down Stocks

Cathie Woods’s ARK Invest deploys $19 million across five growth stocks in this uncertain market.

DKNG : 22.82 (-3.88%)
ARKF : 43.57 (+1.97%)
CMPS : 6.66 (unch)
ARKW : 139.11 (+1.19%)
ARKG : 30.79 (+3.18%)
CNTN : 3.43 (-1.72%)
CERS : 2.08 (+4.00%)
HOOD : 90.75 (+4.49%)
ARKK : 79.23 (+2.44%)
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were issued...

CMPS : 6.66 (unch)

Business Summary

COMPASS Pathways plc is a mental health care company. It operates principally in New York, USA. COMPASS Pathways plc is headquartered in London, UK.

See More

Key Turning Points

3rd Resistance Point 7.29
2nd Resistance Point 7.12
1st Resistance Point 6.89
Last Price 6.66
1st Support Level 6.49
2nd Support Level 6.32
3rd Support Level 6.09

See More

52-Week High 8.90
Last Price 6.66
Fibonacci 61.8% 6.36
Fibonacci 50% 5.57
Fibonacci 38.2% 4.79
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.